Sugi Predict

Sugi Predict / Compounds / SCHEMBL1075868

SCHEMBL1075868

SCHEMBL1075868

CC(C)c1c(C#N)c2ccccc2n1-c1ccc(O)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 5/20 0.42
▸ ALDH1A1 P00352 6/20 0.42
▸ L3MBTL1 Q9Y468 4/20 0.42
▸ LMNA P02545 4/20 0.42
▸ MEN1 O00255 3/20 0.42
▸ GAA P10253 3/20 0.42
▸ KMT2A Q03164 3/20 0.42
▸ MAPT P10636 2/20 0.42
▸ HTT P42858 1/20 0.42
▸ NCOA3 Q9Y6Q9 1/20 0.42
▸ EGFR P00533 1/20 0.39
▸ SRC P12931 1/20 0.39
▸ MAPK1 P28482 3/20 0.38
▸ STAT3 P40763 1/20 0.38
▸ CACNA1B Q00975 1/20 0.38
▸ APBA1 Q02410 1/20 0.38
▸ TRPV1 Q8NER1 1/20 0.37
▸ GLA P06280 2/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ TDP1 Q9NUW8 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1078159 0.84 MAPT (0.46) KDM4EALDH1A1L3MBTL1LMNAMEN1
SCHEMBL1077415 0.81 ALDH1A1 (0.50) KDM4EALDH1A1L3MBTL1LMNAMEN1
SCHEMBL1037222 0.80 ALDH1A1 (0.39) KDM4EALDH1A1L3MBTL1LMNAMEN1
SCHEMBL1076313 0.80 KDM4E (0.46) KDM4EALDH1A1L3MBTL1LMNAMEN1
SCHEMBL23886687 0.79 KDM4E (0.40) KDM4EALDH1A1L3MBTL1LMNAMEN1
SCHEMBL30176314 0.79 KDM4E (0.40) KDM4EALDH1A1L3MBTL1LMNAMEN1
SCHEMBL1075730 0.78 L3MBTL1 (0.44) KDM4EALDH1A1L3MBTL1LMNAMEN1
SCHEMBL13667760 0.78 KDM4E (0.38) KDM4EALDH1A1L3MBTL1LMNAGAA
SCHEMBL1076256 0.78 ALDH1A1 (0.42) KDM4EALDH1A1L3MBTL1LMNAMEN1
SCHEMBL1035637 0.77 ALDH1A1 (0.41) KDM4EALDH1A1L3MBTL1LMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2276732-B1 NOVEL ESTROGEN RECEPTOR LIGANDS KAROBIO AB (SE) 2015-05-20 — — EP claimed
CN-102066323-B Novel estrogen receptor ligands KAROBIO AB 2015-05-13 — — CN claimed
US-8653072-B2 Estrogen receptor ligands KARO BIO AB (SE) 2014-02-18 — — US claimed
US-20130131061-A1 Novel Estrogen Receptor Ligands KARO BIO AB (SE) 2013-05-23 — — US claimed
US-8367665-B2 Estrogen receptor ligands KARO BIO AB (SE) 2013-02-05 — — US claimed
US-20110190294-A1 NOVEL ESTROGEN RECEPTOR LIGANDS OASMIA PHARMACEUTICAL AB (SE) 2011-08-04 — — US claimed
CN-102066323-A Novel estrogen receptor ligands KAROBIO AB 2011-05-18 — — CN claimed
EP-2276732-A1 NOVEL ESTROGEN RECEPTOR LIGANDS KARO BIO AB (SE) 2011-01-26 — — EP claimed
WO-2009127686-A1 NOVEL ESTROGEN RECEPTOR LIGANDS KARO BIO AB (SE) 2009-10-22 — — WO claimed
EP-3782616-B1 ESTROGEN RECEPTOR LIGAND TREATMENT FOR NEURODEGENERATIVE DISEASES UNIV CALIFORNIA (US) 2023-11-01 — — EP disclosed
US-11628146-B2 Estrogen receptor ligand treatment for neurodegenerative diseases THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-04-18 — — US disclosed
EP-3782616-A1 ESTROGEN RECEPTOR LIGAND TREATMENT FOR NEURODEGENERATIVE DISEASES The Regents of The University of California (US) 2021-02-24 — — EP disclosed
US-20210008002-A1 ESTROGEN RECEPTOR LIGAND TREATMENT FOR NEURODEGENERATIVE DISEASES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2021-01-14 — — US disclosed
US-10758496-B2 Estrogen receptor ligand treatment for neurodegenerative diseases THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2020-09-01 — — US disclosed
US-20110190294-A1 NOVEL ESTROGEN RECEPTOR LIGANDS OASMIA PHARMACEUTICAL AB (SE) 2011-08-04 — — US disclosed
US-20110190294-A1 NOVEL ESTROGEN RECEPTOR LIGANDS OASMIA PHARMACEUTICAL AB (SE) 2011-08-04 — — US disclosed
US-20110190294-A1 NOVEL ESTROGEN RECEPTOR LIGANDS OASMIA PHARMACEUTICAL AB (SE) 2011-08-04 — — US disclosed
CN-102066323-A Novel estrogen receptor ligands KAROBIO AB 2011-05-18 — — CN disclosed
EP-2276732-A1 NOVEL ESTROGEN RECEPTOR LIGANDS KARO BIO AB (SE) 2011-01-26 — — EP disclosed
WO-2009127686-A1 NOVEL ESTROGEN RECEPTOR LIGANDS KARO BIO AB (SE) 2009-10-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210008002-A1 ESTROGEN RECEPTOR LIGAND TREATMENT FOR NEURODEGENERATIVE DISEASES ESR2, ESRRG, ESR1 KDM4E 1940/4885ALDH1A1 2803/4885L3MBTL1 3715/4885
US-11628146-B2 Estrogen receptor ligand treatment for neurodegenerative diseases ESR2, ESRRG, ESR1 KDM4E 1940/4885ALDH1A1 2803/4885L3MBTL1 3715/4885
US-20130131061-A1 Novel Estrogen Receptor Ligands ESR1, GPER1, ESRRA KDM4E 405/4885ALDH1A1 1765/4885L3MBTL1 2731/4885
US-20110190294-A1 NOVEL ESTROGEN RECEPTOR LIGANDS ESR1, GPER1, ESRRA KDM4E 379/4885ALDH1A1 1909/4885L3MBTL1 2834/4885
US-10758496-B2 Estrogen receptor ligand treatment for neurodegenerative diseases ESR2, ESRRG, ESR1 KDM4E 1940/4885ALDH1A1 2803/4885L3MBTL1 3715/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.